logo
Plus   Neg
Share
Email

Darden Restaurants Boosts FY19 EPS Outlook; Declares Qtly Dividend - Quick Facts

While reporting financial results for the third quarter on Thursday, Darden Restaurants, Inc. (DRI) raised its outlook for the full-year 2019, based on year-to-date results and its expected performance for the fourth quarter.

Looking ahead to fiscal 2019, the company now projects net earnings from continuing operations in a range of $5.76 to $5.80 per share, up from the prior outlook range of $5.60 to $5.70 per share.

Total sales growth for the year is now forecast at about 5.5 percent, compared to the prior projection for 5.0 to 5.5 percent growth.

Same-restaurant sales growth for the year is now expected in a range of 2.5 to 2.7 percent, compared to the previous forecast for about 2.5 percent growth.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.70 per share on sales growth of 5.4% to $8.52 billion for the year. Analysts' estimates typically exclude special items.

Darden's Board of Directors also declared a regular quarterly cash dividend of $0.75 per share on the Company's outstanding common stock, payable on May 1, 2019 to shareholders of record at the close of business on April 10, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT
>